RegenxBio has patented a method for treating mucopolysaccharidosis II (MPS II) by delivering recombinant human iduronate-2-sulfatase to the central nervous system. The method involves measuring D2S6 levels in a biological sample, diagnosing MPS II, and calculating a ratio of D2S6 to total heparan sulfate disaccharides. GlobalData’s report on RegenxBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on RegenxBio, Adeno-associated virus vectors was a key innovation area identified from patents. RegenxBio's grant share as of May 2024 was 7%. Grant share is based on the ratio of number of grants to total number of patents.